Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2022-04-14

FDA Approved: SYMTUZA — Supplemental Application (Janssen Products LP)

View source ↗

Summary

FDA approved Janssen's supplemental application for SYMTUZA, updating its labeling for the fixed-dose combination of darunavir, cobicistat, emtricitabine, and t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide)

Snippet

SUPPL AP for SYMTUZA (DARUNAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE)